Published online Dec 8, 2023. doi: 10.35711/aimi.v4.i1.1
Peer-review started: July 23, 2023
First decision: August 24, 2023
Revised: October 10, 2023
Accepted: October 30, 2023
Article in press: October 30, 2023
Published online: December 8, 2023
Processing time: 135 Days and 0.6 Hours
The results of this study suggest that computer aided detection (CADe) may not be the right tool for every endoscopist or center. Further studies are needed to understand the impact of CADe on performance quality among endoscopists as well as determine criteria for endoscopists to consider adoption of CADe in their practices.
In this randomised controlled trial performed at a center with high adenoma detection rate (ADR), use of CADe was found to have decreased adenomas per colonoscopy (APC) and ADR.
A total of 244 patients were enrolled (124 with CADe). Use of CADe was found to have decreased number of adenomas (1.79 vs 2.53, P = 0.030) per colonoscopy compared to without CADe. Further, use of CADe was found to have lower ADR (68.5% vs 80.0%, P = 0.041) compared to without use of CADe.
Adults aged 45 or older presenting for screening or low-risk surveillance were randomized to colonoscopy performed with or without CADe. Primary outcomes included ADR, APC, and adenomas per extraction.
The study study is a single-center, prospective, randomized clinical trial, evaluating the utility of CADe in colonoscopy among veterans.
In September 2020, we performed a randomized clinical trial with Food and Drug Administration (FDA) guidance to evaluate the utility of a CADe. This study initially involved five sites, but partway through the study, due to the high baseline ADR of endoscopists (> 40%) at the Veterans Affairs Palo Alto Health Care System, the FDA mandated that this site not be included as part of the company’s pivotal FDA study. As a result, the original study was split into two, into a community-based study involving four sites, and a separate study involving a Veterans hospital. We present the results from the Veterans Affairs Palo Alto Health Care System site.
In an effort to reduce risk for polyp miss rate, multiple quality metrics (such as minimal withdrawal time and ADR have been developed to improve colonoscopy quality. The benefit of CADe has been demonstrated across several studies, including by Repici et al.